Christian Issels @DrisselsIssels - Twitter Profile

Pinned Tweet

almost 2 years ago

This is what Grok had to say about the Issels Immunotherapy as a therapy option for conventional treatment resistant cancers: Based on the information available up to September 13, 2024, Issels Immunotherapy presents a compelling case for being considered an optimal option for cancers resistant to conventional treatments. Here's why: 1. **Non-Toxic Approach**: Issels Immunotherapy's non-toxic nature is particularly appealing for patients who have experienced severe side effects from conventional treatments like chemotherapy or radiation. This approach could potentially improve the quality of life during treatment, which is crucial for patients already weakened by resistant cancers. 2. **Personalized Treatment**: The therapy involves personalized cancer vaccines and cell therapies derived from the patient's own immune cells. This personalization could theoretically address the unique aspects of each patient's cancer, potentially overcoming resistance mechanisms developed against standard treatments. 3. **Targeting Tumor Microenvironment**: Recent insights into cancer biology emphasize the importance of the tumor microenvironment in cancer progression. Issels Immunotherapy specifically targets this microenvironment, which could be key for cancers that have adapted to resist traditional therapies. 4. **Historical Success**: There's mention of an impressive success rate with standard therapy-resistant cancers historically, suggesting that it might have efficacy where other treatments fail. 5. **Comprehensive Approach**: Beyond just targeting cancer cells, Issels Immunotherapy aims to alter the internal environment promoting cancer growth. This holistic approach might address underlying causes of immune suppression, which could be pivotal in cases where cancer has evaded the immune system. However, there are considerations that might affect its status as the "optimal" option: - **Lack of Broad Clinical Data**: While there are testimonials and case studies, broad, peer-reviewed clinical data comparing Issels Immunotherapy directly with other treatments for resistant cancers might be limited. This makes it challenging to definitively claim it as the "optimal" option without more comprehensive studies. - **Cost and Accessibility**: The treatment's personalized nature might make it less accessible due to cost or logistical challenges, which could be significant barriers for many patients. - **Combination Therapies**: The trend in cancer treatment is moving towards combination therapies. While Issels Immunotherapy might be effective on its own, combining it with other novel treatments could potentially yield better results, though this would require further research. - **Patient Variability**: Cancer's response to treatment can be highly variable due to genetic, environmental, and lifestyle factors. What works for one patient might not work for another, even with personalized treatments. - **Ongoing Research**: The field of immunotherapy is rapidly evolving. New treatments or combinations might emerge that could be equally or more effective for treatment-resistant cancers. Given these points, while Issels Immunotherapy could be an optimal choice for some patients with treatment-resistant cancers due to its personalized, non-toxic, and comprehensive approach, it's not universally "optimal" without considering individual patient profiles, the latest research, and comparative effectiveness studies. Patients and oncologists might consider this therapy as part of a broader strategy, potentially in combination with other treatments, or when conventional options have been exhausted. Always, the decision should be made based on the latest medical advice, considering the patient's overall health, cancer type, and treatment history.

7

49

7

8

5K

Christian Issels

@DrisselsIssels

Who to follow

Last Seen Users on Sotwe

Trends for you

Most Popular Users